-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, H7VZogUq74Zp987SQd7earvwWzzrc53ffX6tKf8j3fyS5BVCD8a+QU52jKBBy6v5 92fZs6xDOcmrG+KWtmi6Cw== 0001181431-05-016487.txt : 20050314 0001181431-05-016487.hdr.sgml : 20050314 20050314162634 ACCESSION NUMBER: 0001181431-05-016487 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050314 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20050314 DATE AS OF CHANGE: 20050314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COTHERIX INC CENTRAL INDEX KEY: 0001138812 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50794 FILM NUMBER: 05678709 BUSINESS ADDRESS: STREET 1: 5000 SHORELINE COURT STREET 2: SUITE 101 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-808-6500 MAIL ADDRESS: STREET 1: 5000 SHORELINE COURT STREET 2: SUITE 101 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: EXHALE THERAPEUTICS INC DATE OF NAME CHANGE: 20010503 8-K 1 rrd72479.htm CARDINAL

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 8K

________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): March 10, 2005

CoTherix, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-05794

04-3513144

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. employer identification number)

5000 Shoreline Court, Suite 101, South San Francisco, CA 94080

(Address of principal executive offices and zip code)

(650) 808-6500

(Registrant's telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 1.01 Entry into a Material Definitive Agreement

Effective March 10, 2005, CoTherix, Inc., a Delaware corporation ("CoTherix"), and Cardinal Health PTS, LLC, a Delaware limited liability company, by and through its Specialty Pharmaceutical Services group ("Cardinal Health"), entered into a three-year distribution agreement pursuant to which Cardinal Health will be the exclusive distribution agent to the Company's specialty pharmacy distributors for the commercial sales of Ventavis® (iloprost) inhalation solution in all formulations within the United States.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 14, 2005

CoTherix, Inc.

By:  

/s/ Christine Gray-Smith

Christine Gray-Smith

Executive Vice President and Chief Financial Officer

 

 

 

 

 

 

 

 

 -----END PRIVACY-ENHANCED MESSAGE-----